secwatch.observer — SEC 8-K summary
======================================

Issuer:     Glucotrack, Inc. (GCTK)
CIK:        0001506983
Form:       8-K
Filed at:   2026-05-14T21:27:11+00:00
Accession:  0001493152-26-023202
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glucotrack Q1 net loss $4.3M, IDE submitted to FDA for implantable CGM
----------------------------------------------------------------------

- Net loss $4.3M vs $6.8M YoY; cash $3.9M as of March 31, 2026.
- Submitted Investigational Device Exemption (IDE) to FDA for fully implantable CBGM; targeting U.S. clinical trial launch in 2H 2026.
- Reduced promissory note from $3.6M to ~$1.6M via stock exchange; drew $1.0M under equity line post-quarter.
- R&D expenses $2.1M, G&A $2.1M; cash runway expected into early 3Q 2026.
- Peer-reviewed data in IEEE Sensors and J. Diabetes Research show sensor stability and 6.8% MARD over 240 days.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226023202/0001493152-26-023202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506983/000149315226023202/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer